Sustained Therapeutics

Sustained Therapeutics’ platform technology enables the production of sustained-release formulations of generic drugs. Preliminary data from the lead candidate (ST-01)—from a completed Phase I clinical trials for the treatment of chronic scrotal pain—has demonstrated sustained pain relief over a period of up to four weeks with a single injection.